Stockscreener 앱 받기
3.72
0.00%
0.00
시장 영업 전:
3.94
0.22
+5.91%
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
SAB Biotherapeutics Inc. (SABS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SAB Biotherapeutics Inc. Warrant (SABSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
SAB (SABSW) Session: Moves 7.02% Down to $0.03 at the Close; Boundary Watch - vinanet.vn
SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest SessionCash Secured Put - vinanet.vn
SAB (SABSW) Latest: Falls 14.29% to $0.02 in the Current Update; Level Watch - vinanet.vn
Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW - TradingView
Balyasny Asset Management L.P. Expands Stake in SAB Biotherapeutics Inc (SABS) - GuruFocus
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionROE Trend Analysis - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusCash Flow Strong Stocks - vinanet.vn
Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan
Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan
Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan
Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan
Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan
Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan
Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan
What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat
Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com
SAB Biotherapeutics (SABS) Rises 1.43% to $3.9 — Key Resistance at $4.09 in FocusVolume Spike Alerts - dars.gov.et
SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance
Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds - Investing.com Nigeria
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts Q2 loss after March 2026 stock offering - Stock Titan
SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver Quantitative
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Moomoo
SAB Biotherapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
SAB Biotherapeutics Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
SABS Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Development CostsEarnings Miss Streak - vinanet.vn
SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell - MarketBeat
SAB Biotherapeutics Warrant (SABSW) Jumps 40.85% to $0.02 Amid Renewed Speculative InterestHigh Reward Trades - vinanet.vn
SABSW Edges Higher in Thin Trading: Warrant Holds at $0.01MFI Overbought - vinanet.vn
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABS - TradingView
SABS|SAB Biotherapeutics Inc|Price:3.435|Chg%:-0.075 - TradingKey
SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SABS|SAB Biotherapeutics Inc|Price:3.900|Chg%:+0.050 - TradingKey
SABS Technical Analysis & ETF Price Forecast - Intellectia AI
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey
SABSW Plunges 43% to Penny Level: SAB Biotherapeutics Warrant Hits New LowTechnical Analysis Picks - dars.gov.et
SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
SAB Biotherapeutics Warrants (SABSW) Surge 34%: Low-Priced Derivative Sees Sharp MoveMESA MA - vinanet.vn
SABS|SAB Biotherapeutics Inc|Price:3.510|Chg%:-0.070 - TradingKey
SAB Biotherapeutics (NASDAQ:SABS) Upgraded to "Sell" at Wall Street Zen - MarketBeat
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABSW - TradingView
ETFs Investing in SAB Biotherapeutics, Inc. Stocks - TradingView
SABS Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Biotech Advances PipelineEarnings Stability Report - vinanet.vn
SAB Biotherapeutics (SABS) Slides 3.4% as Stock Tests Key Support LevelsPositive Gamma - dars.gov.et
SABS Q1 2026 Earnings: EPS Misses Estimates Amid Continued Pipeline DevelopmentEarnings Cycle Outlook - vinanet.vn
SAB Biotherapeutics (NASDAQ:SABS) Trading Up 0.6%Still a Buy? - MarketBeat
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance
SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026 $SABS - MarketBeat
SAB Biotherapeutics (SABS) Edges Lower as Stock Tests Key Support LevelsCorrective Wave - DonanımHaber
0.86%
0.31%
자본화:
|
볼륨(24시간):